Oyster mushroom

Oyster Mushroom (Pleurotus ostreatus): A Comprehensive Reference

1. Identity and Taxonomy

Scientific and Common Names

Oyster mushroom, scientifically known as Pleurotus ostreatus, is a macro fungus that belongs to the class Basidiomycetes and the family Pleurotaceae. Its full binomial authority is Pleurotus ostreatus (Jacq.:Fr.) P. Kumm. Common names in English include "oyster mushroom," "pearl oyster mushroom," and "tree oyster mushroom." The oyster mushroom, P. ostreatus (Fr.) P. Kumm, is one of the most economically significant species in the genus, and the second most important commercially cultivated mushroom globally.

Morphology and Natural Source

It is a popular edible mushroom commonly known as the pearl oyster or the tree oyster mushroom. It resembles several other oyster species, often having a shelf-like fruiting body with a pale brown-topped cap. It is native to North America but widely cultivated for food; the taste is said to be mild and the texture very tender, though the short stem or stipe can be tough. It is generally composed of the pileus (cap) and the stipe (stem). Besides feeding on living and dead wood, this fungus also kills and eats nematodes and bacteria.

Related Species and the Genus Pleurotus

There are currently 207 classified species in the genus Pleurotus. The most commercially cultivated species include P. ostreatus (pearl oyster), P. eryngii (king oyster), P. djamor (pink oyster), P. citrinopileatus (yellow oyster), and P. cornucopiae (branched oyster). The blue oyster mushroom, which is also cultivated for food, is a European subspecies.

Common Forms and Preparations

Oyster mushroom is available in several forms for both culinary and supplemental use:

• Fresh fruiting body — the primary culinary form, consumed cooked
• Dried whole mushroom — used in soups, teas, and decoctions; also employed in clinical trials (e.g., as a dried powder)
• Freeze-dried powder — a common form in supplementation and clinical research
• Oven-dried powder — used in fortified foods and clinical studies
• Aqueous and ethanolic extracts — used in pharmaceutical and laboratory research
• Isolated polysaccharide fractions (pleuran, β-glucan extracts) — used in standardized supplements

Pleurotus ostreatus is often viewed as one of the easiest and most cost-effective mushrooms to cultivate at different commercial and experimental scales.

2. Traditional and Historical Use

Within the group of higher fungi, edible medicinal mushrooms have a long history of being used as food and in folk medicine. It is used in traditional medicine to treat infections, hyperlipidemia, diabetes, and cancer.

Various Pleurotus species have been employed throughout history in medicine; for example, they have been used to strengthen joints, tendons, and muscles, improve cardiovascular health, and stimulate the immune system.

Many species of oyster mushroom have been used in folk medicine or Traditional Chinese Medicine, and many species are known to contain chemical substances that have medicinal potential. In Asia, particularly in China, oyster mushrooms have been cultivated for centuries and are a staple in many traditional dishes.

They are used traditionally as a medicine for different diseases. In folklore, mushroom consumption has been linked to diabetes management. Traditional preparations documented in ethnobotanical surveys include powders, infusions, and decoctions. Mushrooms have been used as foods and food flavoring materials in soups and sauces for centuries, due to their unique and subtle flavor.

3. Nutritional Composition

Oyster mushroom (Pleurotus ostreatus) is one of the popular edible mushrooms and is widely cultivated throughout the world for its unique delicacy in flavor, aroma and taste. They exhibit excellent sources of biological proteins, fiber, vitamins, and minerals.

Macronutrient Profile

The proximate composition of Pleurotus ostreatus revealed that it contains 43.42% carbohydrate, 23.63% crude fiber, 17.06% crude protein, 8.22% ash, 1.21% lipid, and a moisture content of 91.01% for fresh samples and 6.46% for dry samples. Oyster mushroom also contains a notable amount of protein (17–23.9 g/100 g dry weight), with the branched chain amino acids (BCAA) — leucine, valine, and isoleucine — being the most abundant.

Dietary Fiber

The fruiting body of P. ostreatus represents a good source of total dietary fiber, consisting of approximately 84% insoluble dietary fiber and 16% soluble dietary fiber. Notably, soluble dietary fiber exerts notable health benefits, as it reduces glycemic response, lowers blood cholesterol and blood pressure, prevents gastrointestinal problems, and provides protection against certain types of cancer.

Vitamins and Minerals

The vitamin profile revealed the presence of vitamin A (2.93 IU/100 g), vitamin C (16.46 mg/100 g), vitamin E (21.50 mg/100 g), and B vitamins, with vitamin B2 having the highest concentration of 92.97 mg/kg. Potassium, iron, and magnesium were the highest minerals present, with 12.25 mg, 9.66 mg, and 7.00 mg amounts, respectively.

4. Key Bioactive Constituents and Mechanisms of Action

The chemical nature of the bioactive compounds present in this mushroom includes polysaccharides, lipopolysaccharides, proteins, peptides, glycoproteins, nucleosides, triterpenoids, lectins, lipids, and their derivatives. In addition, extracts contained alkaloids, tannins, saponins, flavonoids, terpenoids, phenolics, cardiac glycosides, carbohydrates, anthocyanins, and betacyanins in varied amounts.

Beta-Glucans (Pleuran)

The most studied bioactive class in oyster mushroom is its β-glucan polysaccharides. The specific β-glucan isolated from P. ostreatus is commonly called pleuran. β-glucans in P. ostreatus are side-chain/branched (1,3;1,6) polysaccharides, in contrast to the linear (1,3;1,4) β-glucans in oat and barley. P. ostreatus provides approximately twice as many β-glucans as A. bisporus, a dietary fiber that has been gaining much interest due to its beneficial role in the prevention of insulin resistance, dyslipidemia, hypertension, and obesity.

The ability of β-glucans to form highly viscous solutions in the human gastrointestinal tract as well as their fermentability is ascribed to play a key role for their health-related benefits, which are well known from studies with β-glucans from oats and barley. Mechanistically, β-glucans interact with pattern recognition receptors on immune cells, particularly Dectin-1, activating downstream signaling cascades. Real-time polymerase chain reaction array revealed that the expression levels of nuclear factor-κB and Toll-like receptor signaling genes in cells were upregulated by β-glucan treatment. Moreover, the expression of the β-glucan receptor dectin-2 was significantly upregulated, reflecting immune activation through the dectin-2–Syk–(CARD9/Bcl-10/MALT1) pathway.

Lovastatin (Mevinolin)

Mevinolin, also known as lovastatin, acts as an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase — the rate-limiting enzyme in cholesterol biosynthesis. Among mushroom fruiting bodies, Pleurotus ostreatus (Japan) and Agaricus bisporus contained the highest amounts of lovastatin (606.5 and 565.4 mg/kg, respectively). Lovastatin is a naturally occurring secondary metabolite. It has garnered significant attention due to its potent cholesterol-lowering property, mainly achieved through the inhibition of HMG-CoA reductase.

Ergothioneine

Among mushroom fruiting bodies, Pleurotus citrinopileatus, P. ostreatus (Korea), and P. ostreatus (Taiwan) contained the highest amounts of ergothioneine (2850.7, 1829.4, and 1458.4 mg/kg, respectively). Beyond its role as an antioxidant, ergothioneine exhibits immunomodulatory, anti-inflammatory, cytoprotective, and neuroprotective activities, suggesting that it could have medical applications including managing conditions such as neurodegenerative diseases, cardiovascular disorders, and even cancer. The Pleurotus genus contains considerably high amounts of ergothioneine.

Phenolic Compounds and Flavonoids

The antioxidant activity of oyster mushrooms is attributed to the presence of bioactive compounds such as phenolic acids, flavonoids, and polysaccharides. Twelve phenolic compounds have been identified, with 4-hydroxybenzoic acid, trans-cinnamic acid, and trans-o-coumaric acid being predominant. Methanolic extracts of P. ostreatus provided high phenolic content (31.24 mg gallic acid equivalents/g extract) and significant antioxidant activity, scavenging 82.60% and 91.13% of DPPH· and ABTS·+ radicals, respectively.

Anti-Inflammatory Mechanism

Oyster mushrooms, in addition to their nutritional value, demonstrate health-promoting antioxidant, anti-atherosclerotic, anticancer, and immunomodulatory effects. β-glucan isolated from Pleurotus ostreatus inhibited leukocyte migration to acetic acid-injured tissues. At the molecular level, research has demonstrated that the anti-inflammatory activity of edible oyster mushroom is mediated through the inhibition of NF-κB and AP-1 signaling pathways, which are central regulators of inflammation and immune responses.

Lectins and Peptides

Beneficial effects are due to constituents such as polysaccharides, lectins, and peptides. Oyster mushroom lectins have been studied for their antihepatoma activity, and ribonuclease-type peptides isolated from the fungus have been investigated for their potential to inhibit tumor cell proliferation.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular and Lipid-Lowering Effects

Animal Evidence

Administering a 5% dried P. ostreatus powder to male rats decreased serum and liver cholesterol by 33% and 27%, respectively. Again in male rats, oyster mushrooms reduced HMG-CoA reductase activity by more than 30%. The addition of 10% dried fruiting bodies of oyster mushrooms to a rabbit diet containing 1% cholesterol reduced serum cholesterol by 65%, lowered both the incidence of atherosclerotic plaques and plaque size, and prevented atherogenic changes in the aorta and coronary arteries. These preclinical findings are robust across multiple models, but cannot be directly extrapolated to humans.

Human Clinical Evidence

In a small trial in 5 human subjects, 10–15 grams per day of a whole dried European strain of Pleurotus ostreatus mushrooms were ingested over 4 weeks, yielding a 30% reduction in LDL cholesterol levels. This preliminary finding has limited generalizability due to the very small sample size and lack of a control group.

A randomized, controlled intervention study investigated this further. The study for the first time investigated the cholesterol-lowering properties of an oyster mushroom diet in humans. A total of 20 subjects (9 male, 11 female; 20–34 years) were randomized to take either one portion of soup containing 30 g dried oyster mushrooms or a tomato soup as a placebo on a daily basis for 21 days. Standardized blood concentrations of lipid parameters and oxidized low-density lipoprotein were measured at baseline and after 21 days.

A further study examined oyster mushrooms in HIV-positive patients with antiretroviral therapy (ART)-induced hyperlipidemia. Participants received packets of freeze-dried P. ostreatus (15 g/day) to be administered orally for the 8-week trial period. Mean non-HDL cholesterol was 204.5 mg/dL at day 0 and 200.2 mg/dL at day 56. HDL cholesterol levels increased from 37.8 mg/dL to 40.4 mg/dL. Triglycerides dropped from 336.4 mg/dL to 273.4 mg/dL. Only 3 individuals achieved a sustained clinically significant decline in non-HDL cholesterol after 8 weeks of therapy. As administered in this experiment, Pleurotus ostreatus did not lower non-HDL cholesterol in HIV patients with ART-induced hypercholesterolemia. There were no adverse experiences reported other than patients' distaste for the preparation. Liver function tests and muscle enzymes were not affected by the 8 weeks of treatment.

A 2020 PRISMA-guided systematic review compiled the available clinical evidence: In total, eight trials observed beneficial effects of P. ostreatus intake on glucose metabolism (reduction in fasting and/or 2 h postprandial glucose) and lipids (decrease in total cholesterol, LDL-cholesterol, and/or triglycerides), and some found a reduction in blood pressure. In contrast, body weight did not change. However, the authors noted considerable heterogeneity across trials in terms of dose, preparation, and participant populations, and identified risk of bias concerns in many included studies. Overall, the clinical lipid-lowering evidence is preliminary and mixed — the systematic review suggests a trend toward benefit, but individual trials are small and methodologically variable.

5.2 Blood Glucose Regulation and Antidiabetic Effects

Mechanism

The ability of β-glucans to form highly viscous solutions in the human gastrointestinal tract as well as their fermentability is ascribed to play a key role for their health-related benefits. Viscous soluble fiber slows gastric emptying and the absorption of glucose, blunting postprandial glycemic responses. Additionally, α-glucosidase inhibition by phenolic compounds in P. ostreatus may slow dietary carbohydrate digestion.

Human Evidence

A randomized controlled crossover trial specifically studied postprandial metabolism in individuals with impaired glucose tolerance (IGT). In this study, 22 subjects with IGT ingested a meal either enriched with 20 g powder (8.1 g β-glucans) of oven-dried Pleurotus ostreatus or without enrichment. Postprandial glucose, insulin, triglycerides, GIP, and ghrelin concentrations as well as the corresponding AUCs did not differ between the enriched and control meals. However, non-esterified free fatty acids (NEFAs) AUC was 14% lower (P = 0.026) and GLP-1 AUC 17% higher (P = 0.001) after the enriched meal compared to control. This suggests a modest improvement in metabolic signaling rather than a direct glycemic effect at this dose.

Oyster mushroom improved postprandial metabolism in patients with impaired glucose tolerance and exhibited hypoglycemic activity in diabetic patients in separate reported studies. However, human clinical evidence for antidiabetic effects remains limited in quantity and quality. Larger, well-controlled randomized trials are needed.

Animal Evidence

Blood glucose level and biochemical parameters were studied in alloxan-induced diabetic mice after 15 days of treatment. Animals treated with the ethanolic extract of P. ostreatus showed a significant decrease in serum glucose level (P < 0.01). Multiple rodent studies have demonstrated hypoglycemic effects, but these are not directly translatable to human outcomes.

5.3 Immunomodulatory Effects and Respiratory Tract Infections

Mechanism

Both immunomodulatory and anti-inflammatory effects of mushrooms have been described using purified β-glucans or fungi extracts on cellular and experimental models; their potential clinical use has been tested in different conditions, such as recurrent infections of the respiratory tract or complications of major surgery.

Human Clinical Evidence

The most investigated application of pleuran (the specific β-glucan of P. ostreatus) in humans is immunomodulation in the context of respiratory infections. The immunomodulatory effect of β-glucans (a syrup containing the pleuran β-glucan from Pleurotus ostreatus and vitamin C) has been tested versus vitamin C alone in a clinical trial in children with recurrent respiratory tract infections: the respiratory symptoms were reduced, but the beneficial effect cannot be attributed to the β-glucans alone, rather should be related to a potentiating effect by β-glucan of vitamin C.

A randomized, double-blind, placebo-controlled study with pleuran, the β-glucan isolated from Pleurotus ostreatus, showed a significant reduction of peripheral blood eosinophilia and stabilized the levels of total immunoglobulin E in serum in children with recurrent respiratory tract infections, suggesting a potential immunomodulatory benefit.

Jesenak (2013) reported significant reductions in respiratory tract infections in children given 100 mg of pleuran daily for 24 weeks. In athletes, pleuran improved immune performance and reduced infection rates.

Evidence in Breast Cancer Patients

A study aimed to evaluate the effect of pleuran (β-glucan from oyster mushroom) on the selected immune parameters of patients with breast cancer in remission. The researchers studied antitumor cellular immune parameters of 195 patients (49 in the pleuran group and 146 in the control group) by means of flow cytometry. After 12 months, a significant increase of cytotoxic T lymphocytes was measured in the pleuran group compared with a significant decrease in the control group. The results suggest potential benefit of long-term administration of pleuran on antitumor cellular immunity and better prognosis in breast cancer patients in remission. This is an important human study, though it was not a double-blind placebo-controlled trial in the strictest sense, and the results require replication.

Overall, the immunomodulatory evidence for pleuran is among the most developed areas of human clinical research for oyster mushroom, with multiple trials in pediatric and adult populations, though study sizes remain moderate and long-term efficacy data are still limited.

5.4 Antioxidant Activity

Oyster mushrooms have been shown to possess antioxidant properties. Studies have demonstrated that oyster mushroom extracts can scavenge free radicals, reduce oxidative stress, and protect against cell damage. It has gained increasing attention due to its remarkable nutritional and functional profile, emphasizing its potential as a source of bioactive compounds with antioxidant, anti-inflammatory, hypolipidemic, and immunomodulatory properties. This evidence is primarily in vitro and based on cell-free radical-scavenging assays; robust human trial data specifically measuring clinical antioxidant outcomes are lacking.

5.5 Anti-Inflammatory Effects

In preclinical models (cell culture and animal studies), oyster mushroom extracts and isolated β-glucans have demonstrated significant anti-inflammatory effects. The primary identified mechanism involves inhibition of NF-κB and AP-1 transcription factors, which govern the expression of pro-inflammatory mediators including TNF-α, IL-6, and COX-2. A randomized controlled trial combining Pleurotus eryngii with antioxidant compounds and vitamin D2 demonstrated a reduction in multiple markers of systemic inflammation, including CRP and TNF-α. Direct human trial evidence for anti-inflammatory effects specific to P. ostreatus alone remains preliminary.

5.6 Anticancer Properties

Preclinical studies suggest antitumor, immunomodulatory, antifungal, lipid-lowering, and hypoglycemic properties. It has been proven in numerous studies that P. ostreatus offers many health-promoting benefits such as anticancer, antioxidant, antitumor, antiviral, antibacterial, antidiabetic, and anti-hypercholesteremic activities. However, the anticancer evidence for P. ostreatus is currently largely preclinical (cell culture and animal studies). The immunomodulatory pleuran study in breast cancer patients (described above) is one of the few human studies touching on this domain. No randomized controlled clinical trials have yet demonstrated direct antitumor efficacy of oyster mushroom in human cancer treatment.

5.7 Skin Health

A goal of one study was to evaluate the soothing effect of a β-glucan pleuran-based cream against skin alterations caused by a solar simulator (UVA/UVB exposure) and to assess the efficacy of the cream after 30 days of use on the face and body in 20 human subjects with all skin types (sensitive, atopic, and normal) and phototypes II and III. β-D-glucans represent a class of natural compounds, and their use in the cosmetic and pharmaceutical industries is increasing. This represents a small but emerging area of topical application; evidence is currently very preliminary.

6. Body Systems and Health Areas Associated with Oyster Mushroom

• Cardiovascular system — lipid lowering (via lovastatin-like HMG-CoA reductase inhibition and β-glucan fiber), blood pressure modulation
• Metabolic / endocrine system — blood glucose regulation, α-glucosidase inhibition, improved postprandial GLP-1 signaling
• Immune system — immunomodulation via β-glucan/pleuran acting on Dectin-1 and NF-κB pathways, reduction of respiratory tract infection frequency
• Gastrointestinal system — prebiotic fiber fermentation, viscosity-mediated modulation of nutrient absorption
• Inflammatory pathways — inhibition of NF-κB, AP-1, TNF-α, IL-6, and COX-2
• Antioxidant defense — free radical scavenging via phenolics, flavonoids, ergothioneine, and polysaccharides
• Oncology-adjacent immune support — pleuran-mediated cytotoxic T-lymphocyte enhancement in breast cancer remission patients
• Skin — topical pleuran cream application for UV-induced erythema and skin parameter improvement

7. Dosage Forms and Dosages Reported in Studies

The following dosages are reported directly from peer-reviewed clinical studies and should not be interpreted as recommendations:

• Freeze-dried powder, oral: 15 g/day administered orally for an 8-week trial period (HIV-related hyperlipidemia study).
• Dried whole mushroom as soup ingredient: One portion of soup containing 30 g dried oyster mushrooms daily for 21 days (lipid-lowering RCT in young adults).
• Dried mushroom powder (oven-dried), in food: 20 g powder (8.1 g β-glucans) of oven-dried Pleurotus ostreatus added to a single meal (postprandial crossover study in IGT subjects).
• Whole dried mushroom (early human trial): 10–15 grams per day of a whole dried European strain of Pleurotus ostreatus ingested over 4 weeks (small 5-subject cholesterol study).
• Pleuran (isolated β-glucan), oral supplement: 100 mg of pleuran daily for 24 weeks (pediatric respiratory tract infection trial).

It should be noted that consumption of P. ostreatus, an edible oyster mushroom rich in functional ingredients (e.g., β-glucans), may improve glucose and lipid metabolism, blood pressure, body weight, and appetite sensations. A systematic review aimed to provide an overview on the effects of P. ostreatus intake on cardiometabolic parameters from clinical trials, taking into account risk of bias. Standardized dosage guidelines have not been established by any pharmacopeia or regulatory body.

8. Safety, Adverse Effects, and Interactions

General Safety Profile

No adverse experiences were reported other than patients' distaste for the preparation. Liver function tests and muscle enzymes were not affected by 8 weeks of treatment at 15 g/day. In acute toxicity assessments in animal models, P. ostreatus has demonstrated a wide safety margin, though formal human toxicology studies are limited.

Allergic Reactions — Ingestion

Nausea, vomiting, shortness of breath, and chest pain were reported in a 31-year-old woman 2 hours after eating oyster mushrooms. An allergy test and complete resolution after treatment confirmed this as the source of her reactions. Acute coronary syndrome has been reported in a 31-year-old woman 2 hours after the ingestion of oyster mushroom.

Occupational Allergy and Respiratory Sensitization

Occupational asthma, widespread lung inflammation, and severe allergic reaction have been reported following exposure to oyster mushroom spores. A constant exposure of indoor mushroom cultivators to Pleurotus ostreatus spores increases the risk of respiratory allergy development. A documented case report in International Journal of Occupational Medicine and Environmental Health described a mushroom farm worker who, during packing and sorting mushrooms, felt dyspnea accompanied by weakness, rapid pulse, and skin itching with urticaria. Spirometry performed immediately after one of the exposures showed a reduced airflow obstruction. Prick-to-prick test with oyster mushrooms yielded a positive result (wheal size of 12 mm), and increased total IgE (78 iu/ml) in serum was recorded. The patient was diagnosed with occupational anaphylaxis and work-related asthma.

Basidiomycetes spores from edible mushrooms are a very rare cause of respiratory allergies. The patient's history, the immediate positive skin reactions in the prick-to-prick tests, and the demonstration of a significant amount of IgE to shiitake and oyster extracts supported the allergic, IgE-dependent pathogenesis of occupational asthma.

A constant exposure of indoor mushroom cultivators to Pleurotus ostreatus spores increases the risk of respiratory allergy development. Environmental monitoring of oyster mushroom spores is reasonable in the industry, as it may prove useful in the prevention of the disease.

Drug Interactions

Because P. ostreatus contains a natural lovastatin-like compound, a clinically relevant interaction consideration exists. Standard treatments for hypercholesterolemia include the HMG-CoA reductase inhibitors, or "statins." Because many antiretroviral therapy (ART) agents and statins share a common metabolic pathway that uses the cytochrome P450 enzyme system, co-administration of ART with statins could increase statin plasma levels significantly. By extension, combining high amounts of oyster mushroom (particularly lovastatin-containing preparations) with pharmaceutical statins or CYP450-metabolized drugs warrants attention. The serious muscle damage including myopathy may occur due to continuous intake of lovastatin tablets, hence identification of natural lovastatin sources is crucial.

Given the documented hypoglycemic activity in animal and human studies, additive blood glucose-lowering effects are a theoretical concern when oyster mushroom supplements are co-administered with antidiabetic medications.

Evidence Strength Summary

Studies in humans are limited. The strongest body of human clinical evidence exists for immunomodulatory effects of isolated pleuran (β-glucan), particularly regarding respiratory tract infections, where multiple randomized controlled trials have been conducted. Lipid-lowering and antidiabetic effects show consistent preclinical support and preliminary positive trends in human trials, but are limited by small sample sizes, variable preparations, and methodological heterogeneity. Antioxidant, anti-inflammatory, and anticancer effects are supported primarily by in vitro and animal data; direct human clinical evidence remains insufficient to draw firm efficacy conclusions for these areas.

References

• Nutritional and Bioactive Properties of an Amazon Wild Oyster Culinary-Medicinal Mushroom, Pleurotus ostreatus (Agaricomycetes) — PubMed
• Nutritional quality of Oyster Mushroom (Pleurotus ostreatus) as affected by osmotic pretreatments and drying methods — PMC
• Assessing the nutritional quality of Pleurotus ostreatus (oyster mushroom) — PubMed
• Centesimal Composition, Bioactive Compounds, Antioxidant and α-Glucosidase Inhibitory Activities of Commercial Edible Oyster Mushrooms — PMC
• Comparative antioxidant activity and phytochemical content of five extracts of Pleurotus ostreatus — PMC
• Green Valorization Strategies of Pleurotus ostreatus and Its By-Products — PMC
• Bioactive compounds, nutraceutical values and its application in food product development of oyster mushroom — ScienceDirect
• Antihyperlipidemic effects of Pleurotus ostreatus (oyster mushrooms) in HIV-infected individuals taking antiretroviral therapy — PMC / BMC Complementary Medicine and Therapies
• Effect of the Intake of Oyster Mushrooms (Pleurotus ostreatus) on Cardiometabolic Parameters — A Systematic Review of Clinical Trials — PMC
• Lipid lowering effects of oyster mushroom (Pleurotus ostreatus) in humans — ScienceDirect
• Immunomodulation with β-glucan from Pleurotus ostreatus in patients with endocrine-dependent breast cancer — PubMed
• Edible Mushrooms and Beta-Glucans: Impact on Human Health — PMC
• Pleuran-β-Glucan from Oyster Culinary-Medicinal Mushroom, Pleurotus ostreatus (Agaricomycetes), Soothes and Improves Skin Parameters — PubMed
• Immunomodulatory Effects of Extracellular β-Glucan Isolated from the King Oyster Mushroom Pleurotus eryngii — PubMed
• Antioxidant and Anti-Inflammatory Activity of Five Medicinal Mushrooms of the Genus Pleurotus — PMC
• Fortifying a meal with oyster mushroom powder beneficially affects postprandial glucagon-like peptide-1, non-esterified free fatty acids and hunger sensation in adults with impaired glucose tolerance — PMC
• Evaluation of antidiabetic potential of oyster mushroom (Pleurotus ostreatus) in alloxan-induced diabetic mice — PubMed
• Hypoglycemic and Antidiabetic Effect of Pleurotus sajor-caju Aqueous Extract in Normal and Streptozotocin-Induced Diabetic Rats — PMC
• Anti-inflammatory activity of edible oyster mushroom is mediated through the inhibition of NF-κB and AP-1 signaling — PMC
• Anti-Inflammatory Activity of Pleurotus ostreatus, a Culinary Medicinal Mushroom, in Wistar Rats — PMC
• Contents of lovastatin, γ-aminobutyric acid and ergothioneine in mushroom fruiting bodies and mycelia — ScienceDirect
• Ergothioneine: An Antioxidative, Neuroprotective and Anti-Inflammatory Compound from Mushroom Residuals — PMC
• A case of anaphylactic reaction following oyster mushroom (Pleurotus ostreatus) inhalation — PubMed
• Allergic asthma to shiitake and oyster mushroom — ResearchGate / Semantic Scholar
• Oyster Mushroom — Memorial Sloan Kettering Cancer Center Integrative Medicine
• The Food and Medicinal Benefits of Oyster Mushroom (Pleurotus ostreatus): A Review — International Journal of Pharmaceutical Sciences and Research
• Screening of Antimicrobial Properties and Bioactive Compounds of Pleurotus ostreatus Extracts — PMC
• Impact of substrate methionine content on lovastatin potentiation and morphological parameters of Pleurotus ostreatus — ScienceDirect
• Oyster Mushroom Clinical Overview — mushroomclinicaltrials.com